GARRETSON, SD--(Marketwired - Mar 3, 2014) - Braasch Biotech LLC, a biopharmaceutical company developing and commercializing anti-somatostatin vaccines, today announced that it has received a Notices of Acceptance from the Australian and Japanese Patent Offices for a patent covering the use of Braasch's product candidate, JH14-Somatovac®. The vaccine is indicated for use in livestock and safely enhances the target animal's own ability to produce more protein, without non-desirable side events as in current pharmaceuticals.